Exact Sciences Corp
NASDAQ:EXAS
Exact Sciences Corp
NASDAQ:EXAS
Price:
60.54 USD
0.88%
Market Closed
Updated:
May 3, 2024
Section:
Relative Value
The Relative Value of one
EXAS
stock under the Base Case scenario is
115.64
USD.
Compared to the current market price of 60.54 USD,
Exact Sciences Corp
is
Undervalued by 48%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EXAS
Relative Value
Base Case
115.64
USD
Undervaluation 48%
Valuation Multiples
Multiples Across Competitors
EXAS Competitors Multiples
Exact Sciences Corp Competitors
Exact Sciences Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
11B USD | 4.4 | -53.8 | -1 609.1 | -58.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
149.1B USD | 5.3 | 22.2 | 16.5 | 24.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.1B USD | 10.4 | 28.5 | 22.8 | 23.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
102.6B USD | 7.8 | 25.9 | 17.4 | 19.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.2 | 35.4 | 21.4 | 26.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.4B USD | 3 | 168.2 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48B USD | 7 | -10.2 | -11 | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 3.2 | 26.6 | 13.7 | 17.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
